These results suggest that long-term palopegteriparatide therapy in adults with chronic hypoparathyroidism gradually returns the skeleton toward its natural state thereby enhancing the skeleton's contribution to calcium homeostasis.
Study context
Population
Adults with chronic hypoparathyroidism treated with palopegteriparatide
Outcome
BMD, serum bone turnover markers, serum and urine calcium
Follow-up
Through 3 years (week 162)
Methodological details3-year follow-up
3-year follow-up
Main finding
As reported in the abstract
Independent from conventional therapy at week 162
91%
Original publication
Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. J Bone Miner Res. Published 4 February 2026. doi:10.1093/jbmr/zjag013